6632-63-9

Usage

Uses

Used in Pharmaceutical Industry:
NSC45719 is used as an anti-cancer agent for its ability to effectively inhibit the activity of PDK1, leading to the suppression of tumor growth in various cancer cell lines.
Used in Research and Development:
NSC45719 is used as a valuable tool for further investigation into PDK1 signaling pathways, aiding in the development of targeted therapeutics for diseases characterized by dysregulated PDK1 activity.
Used in Treatment of Diabetes and Cardiovascular Disorders:
NSC45719 is used as a potential treatment for diseases such as diabetes and cardiovascular disorders, due to its promising potential in addressing dysregulated PDK1 activity in these conditions.

InChI:InChI=1/C5H5ClN2OS/c1-10-5-7-3(6)2-4(9)8-5/h2H,1H3,(H,7,8,9)

Upstream product

• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 

Downstream Products

• 151699-85-3 6-Benzyloxy-2-methylsulfanyl-pyrimidin-4-ol 
• 151699-86-4 6-(benzyloxy)-4-(difluoromethoxy)-2-(methylthio)pyrimidine 
• 1979-96-0 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 
• 1097966-93-2 4-(N-benzylamino)-6-chloro-2-methylthio-5-nitropyrimidine 

Relevant academic research and scientific papers

HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.

Identification and Synthesis of a Unique Disulfide Dimeric Metabolite of Primisulfuron-methyl in the Mouse

The major metabolic pathway for primisulfuron-methyl in animals involves hydroxylation of the pyrimidine ring followed by conjugation.This investigation found a unique metabolite in mice fed at high feeding levels (>5000 ppm) of the compound.The unique metabolite is identified as a disulfide dimer of the parent compound, and its synthesis is reported.